摘要
目的:应用超声心动图观察右丙亚胺对吡喃阿霉素(吡柔比星,THP)所致心脏毒性的防治作用。方法:将接受吡柔比星化疗的非霍奇金淋巴瘤患者30例随机分为单纯化疗组及右丙亚胺组各15例,右丙亚胺组在常规化疗基础上,加用右丙亚胺静滴。在化疗第1疗程(T1)开始前、第3疗程(T3)及第6疗程(T6)结束后行超声心动图检测,记录EF、E/A及TDI技术测量E'/A'、PW/PW法测量Tei指数,观察化疗前后吡柔比星对上述指标的影响,以及右丙亚胺对其心脏毒性的防治效果。结果:组间比较,T3结束后,单纯化疗组及右丙亚胺组EF及E/A差异无统计学意义(P>0.05),E'/A'及Tei指数有统计学意义(P<0.05)。T6结束后,单纯化疗组及右丙亚胺组EF及E/A差异存在统计学意义(P<0.05),E'/A'及Tei指数亦存在有统计学意义(P<0.05)。组内比较,与T1比较,单纯化疗组在T3结束后EF及E/A差异无统计学意义(P>0.05),而E'/A'及Tei指数有统计学意义(P<0.05),在T6结束后,单纯化疗组与T1比较,其EF、E/A、E'/A'及Tei指数均存在统计学意义(P<0.05);右丙亚胺组在T3、T6结束后,与T1比较,其EF、E/A、E'/A'及Tei指数的差异均无统计学意义(P>0.05)。结论:右丙亚胺对吡柔比星化疗所致的心脏毒性具有一定的防治作用,TDI及Tei指数能够较EF及E/A更早、更敏感评估患者心脏功能的变化。
Objective:Evaluated the prevention role for cardiotoxicity induced by theprubicin chemotherapy and dexrazoxane. Methods:Thirty nonlymphocytic leukemia patients undergoing a 6 - cycle chemotherapy regimen were divided into two groups:THP group (n=15,treated with thepubicin alone) and T - D group (n 15,treated combined with thepubicin and dexrazoxane). Echocardiography study were performed on the first eyrie (T1), middle (T3) ,and at the end (T6). Results:Compared THP and T - D groups:After T3,there were significant differences in E'/A' (decreased) and Tei index (pralonged) in THP group (P 〈0.05) ,but not in left veutride ejection fraction (EF) and E/A ration (P 〉 0.05). After T6, significant differences were found on EF (decreased), E/A ( decreased) ,E'/A' (decreased) and Tei index (prolonged) in THP group (P 〈 0.05). Before and after treatment : after T3,E'/A' and Tel index were significantly changed in THP group compared to T1 (P 〈 0.05), but not in EF and E/A (P 〉0.05). After T6,EF,E/A,E'/A'and Tel index were significant different in THP group(P 〈0.05). After T3 and T6,there were no differences among EF, E/A, E'/A' and Tel index in T - D group (P 〉 0.05). Conclusion: Dexrazoxane can prevent theprubiein eardiotoxieity in nonlymphoeytie leukemia patients. E'/A'and Tel index may be the sensitive markers for detecting early theprubiein - induced eardiotoxieily.
出处
《现代肿瘤医学》
CAS
2014年第2期428-430,共3页
Journal of Modern Oncology
基金
广东省科技计划项目(编号:2010B080701055)